Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Dr Reddys recalls...

    Dr Reddys recalls Ranitidine products in US over cancer-causing impurity

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-10-24T09:30:53+05:30  |  Updated On 17 Aug 2021 10:49 AM IST

    This recall follows the USFDA's caution note alerting patients and healthcare professionals that NDMA was found in certain samples of ranitidine, Dr Reddys said in a filing.


    New Delhi: Dr Reddy's Laboratories on Wednesday said it has initiated a voluntary nationwide recall of all its ranitidine medications sold in the US due to contamination with probable cancer-causing N-Nitrosodimethylamine (NDMA).


    The recall started on October 1 after the United States Food and Drug Administration (USFDA) found the presence of NDMA in certain ranitidine products above the permissible levels.


    NDMA is classified as a probable human carcinogen based on results from laboratory tests. NDMA is a known environmental contaminant and found in water and foods, including meats, dairy products, and vegetables.


    The recall has been initiated at the retail level for over-the-counter products and at the consumer level for prescription products of all of its ranitidine medications sold in the US due to confirmed contamination with NDMA above levels established by the USFDA, Dr Reddy's said in a filing to the BSE.


    Read Also: Dr Reddys Chairman Satish Reddy named as New President of Indian Pharmaceutical Alliance


    This recall follows the USFDA's caution note alerting patients and healthcare professionals that NDMA was found in certain samples of ranitidine, it added.


    "To date, Dr Reddy's has not received any reports of adverse events related to the recall of Dr Reddy's Ranitidine products. The recall includes all quantities in the US that are within expiry," the company said.


    All ranitidine products with expiration dated September 2019 to June 2021 are being recalled, it added. Last month, drug firm Strides too recalled its ranitidine tablets in the US due to contamination with NDMA.


    Read Also: Dr Reddys gets Establishment Inspection Report from USFDA for Bollaram facility

    BSEcancercarcinogenDr ReddyDr Reddy LaboratoriesDr Reddy'sDr Reddy's LaboratoriesDr Reddy's LabsHealthcareN-nitrosodimethylamineNDMApharmapharma companypharma newsranitidineUnited States Food and Drug AdministrationUSFDA
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok